Global Opioid Induced Constipation Market Size By Active Ingredients(Naloxegol, Lubiprostone, Methylnaltrexone Bromide), By Prescription Type(Over The Counter, Prescription), By End-User(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geographic Scope And Forecast

Opioid Induced Constipation Market Size And Forecast

Opioid Induced Constipation Market size was valued at USD 1,452.29 Million in 2021 and is projected to reach USD 2,371.32 Million by 2030, growing at a CAGR of 5.9% from 2023 to 2030.

The growth in renal problems can be ascribed to lifestyle changes such as eating calcium and other mineral-rich foods. Several diverse remedies are offered for the sick state, which is leading to market expansion. The Global Opioid Induced Constipation Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Opioid Induced Constipation Market Definition

The activation of enteric -opioid receptors reduces bowel tone and contractility while increasing colonic fluid absorption and anal sphincter tone while decreasing rectal feeling. This results in firmer stools that are more difficult to clear. They ultimately classified OIC as a change in bowel habits following opioid beginning that involves any of the following symptomsdecreased bowel movement frequency, onset or worsening of straining to evacuate stool, a perception of incomplete rectal evacuation, and tougher stool consistency.

Opioid-induced constipation is a condition that is commonly caused by the use of opioid pain relievers such as morphine, codeine, hydrocodone, and others. The therapeutic effect of these medications is highly effective in pain relief, but in the majority of cases, it causes particular types of constipation. The opioids’ attachment to the receptors in the stomach lengthens the time it takes for stool to transit through the gastrointestinal tract. This results in bowel movements being limited to three times a week. As a result, effective therapy is required to alleviate the pain associated with this illness.

Global Opioid Induced Constipation Market Overview

So, we're seeing more kidney issues these days, and a lot of it comes down to how we live – like eating foods packed with calcium and other minerals. Luckily, there are tons of different ways to treat these problems, which is making the market for solutions bigger and bigger. For example, there's lubiprostone, which helps with constipation caused by things like opioid painkillers. It's mainly used for chronic idiopathic constipation (CIC), and experts think it'll become more popular than methylnaltrexone bromide. Plus, naloxegol is expected to grow really fast over the next few years. They're even testing these medications on different groups of people, like pregnant women and kids under 17. Because of all this research, we're expecting lots of new approvals soon, which will really shake up the market. Exciting times!

The opioid-induced constipation (OIC) medication market is looking up! We're seeing more of these medications dispensed at your local pharmacy, and there are also more pharmacies popping up in developed countries. People often prefer the convenience of getting their prescriptions filled at retail pharmacies. Plus, some older drugs are losing their patent protection, which could mean new opportunities for companies entering the market. Combination therapies are also becoming more popular, boosting the market. But, it's important to remember that some patients can develop a tolerance and need more and more medication for pain relief. Long-term opioid use can also lead to dependence, and stopping the medication can cause unpleasant withdrawal symptoms like anxiety, drug cravings, irritability, and even tremors. Learn more about opioid dependence.

Global Opioid Induced Constipation MarketSegmentation Analysis

The Global Opioid Induced Constipation Market is Segmented on the basis of Active Ingredients, Prescription Type, End-User And Geography.

Opioid Induced Constipation Market, By Active Ingredients

• Naloxegol• Lubiprostone• Methylnaltrexone Bromide• Docusate Sodium• Others

On the basis of Active Ingredients, the market is segmented into Naloxegol, Lubiprostone, Methylnaltrexone Bromide, Docusate Sodium, Others. Lubiprostone accounted for the largest market share in the global market owing to benefits and advanatges offered by it. Lubiprostone is used to treat opioid-induced constipation, with the main indication being chronic idiopathic constipation (CIC). Lubiprostone is expected to overtake methylnaltrexone bromide’s market share. Furthermore, during the forecast period, naloxegol is expected to increase at the fastest CAGR. The medicine is being tested for a variety of patient populations, including pregnant women and children under the age of 17.

Opioid Induced Constipation Market, By Prescription Type

• Over The Counter• Prescription

When it comes to how you get these remedies, the market is split into two main typesOver The Counter and Prescription. Right now, Over The Counter options are really popular, grabbing a big slice of the global market. This is partly because more people are choosing them and because governments are backing them. Need something mild? You can find stool softeners over-the-counter, like docusate (Colace) and docusate calcium (Surfak). They basically help your colon hold onto more water, making things easier to pass. Or, you might try stimulants such as biscacodyl (Ducodyl, Dulcolax) and senna-sennosides (Senokot). These guys give your bowels a little kick to get things moving. Then there are osmotics, which pull fluid into your colon. Think oral magnesium hydroxide (Phillips Milk of Magnesia) and polyethylene glycol (MiraLAX). Finally, there's mineral oil, a lubricant laxative that helps stool slide through. You can snag it over-the-counter in either oral or rectal forms.

Opioid Induced Constipation Market, By End-User

• Hospital Pharmacies• Retail Pharmacies• Online Pharmacies

When we look at where people get their medications, the opioid-induced constipation (OIC) market breaks down into a few key placesHospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Right now, Hospital Pharmacies are the biggest piece of the pie. These pharmacies stock up on drugs directly from the manufacturers to treat patients who are either staying at the hospital or just visiting. You'll find all sorts of medications there, especially those for critical care and specific therapies used in areas like cardiology, neurology, and even treating infections or blood disorders. Essentially, hospital pharmacies are there to get, keep safe, and then give out the medications that hospital patients need while they're getting treatment.

Opioid Induced Constipation Market, By Geography

• North America• Europe• Asia Pacific• Latin America• Middle East and Africa

Based on regional analysis, the Opioid Induced Constipation Market is classified into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America accounted for the largest market share in the global market due to the strong presence of key players and rising R&D activity. Due to increased new research and development on opioid-induced constipation medications industry, Asia-Pacific controls the market. The growing availability of modern healthcare infrastructure and quicker approval of opioid-induced constipation medications as a result of the FDA’s rapid drug approval effort are expected to drive market expansion in this region.

Key Players

The “Global Opioid Induced Constipation Market” study report will provide valuable insight with an emphasis on the global market including some of the major players such as Bayer, Takeda Pharmaceuticals, Sanofi, Salix (Bausch Health), Mallinckrodt, AstraZeneca, Purdue Pharm, Nektar Therapeutics, Progenics Pharmaceuticals, Daiichi Sankyo, GSK, Prestige, Shionogi.

Key Developments

• Takeda has announced that the generic medication Lubiprostone will be available in 2021. Lubiprostone is prescribed to treat both chronic idiopathic constipation and opioid-induced constipation.

• Sandoz Pharmaceutical Company and Shionogi and Co Ltd agreed in 2019 to launch Rizmoic medication in the European market. Rizmoic is a novel medication used to treat opioid-induced constipation in adults.

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.

Market Attractiveness

The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Opioid Induced Constipation Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.

Porter’s Five Forces

The image provided would further help to get information about Porter’s five forces framework providing a blueprint for understanding the behavior of competitors and a player’s strategic positioning in the respective industry. The porter’s five forces model can be used to assess the competitive landscape in Global Opioid Induced Constipation Market gauge the attractiveness of a certain sector, and assess investment possibilities.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

We take a deep dive into the market using both qualitative and quantitative analysis, breaking it down into segments based on all sorts of things, not just money. You'll get market value data (in USD Billion) for every segment and sub-segment, and we'll even pinpoint the region and segment we think will grow the fastest and be the biggest. We'll give you a regional breakdown, showing you where the product/service is being used and the why behind each region's market. Plus, we'll map out the competitive landscape, including a ranking of the big players and all the new launches, partnerships, expansions, and acquisitions they've made in the last five years. Think detailed company profiles with overviews, insights, product comparisons, and even SWOT analyses. We'll paint a picture of the current and future market, highlighting the opportunities, drivers, challenges, and restraints in both emerging and developed regions. We'll also analyze the market from different angles using Porter's five forces, give you the Value Chain scoop, and explore the market's dynamics and growth opportunities in the years ahead. Oh, and you get 6 months of post-sales analyst support to help you make sense of it all.

Customization of the Report

• In case of any  please connect with our sales team, who will ensure that your requirements are met.